

SLCO1B3 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP18964b

Specification

SLCO1B3 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

Q9NPD5

SLCO1B3 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 28234

Other Names

Solute carrier organic anion transporter family member 1B3, Liver-specific organic anion transporter 2, LST-2, Organic anion transporter 8, Organic anion-transporting polypeptide 8, OATP-8, Solute carrier family 21 member 8, SLC01B3, LST2, OATP1B3, OATP8, SLC21A8

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SLCO1B3 Antibody (C-term) Blocking Peptide - Protein Information

Name SLCO1B3

Synonyms LST2, OATP1B3, OATP8, SLC21A8

Function

Mediates the Na(+)-independent uptake of organic anions (PubMed:15159445, PubMed:17412826, PubMed:10779507). Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (17-beta- glucuronosyl estradiol, dehydroepiandrosterone sulfate (DHEAS), and estrone 3-sulfate), as well as eicosanoid leukotriene C4, prostaglandin E2 and L-thyroxine (T4) (PubMed:15159445, PubMed:17412826, PubMed:10779507, PubMed:12568656, PubMed:11159893, PubMed:19129463). Hydrogencarbonate/HCO3(-) acts as the probable counteranion



that exchanges for organic anions (PubMed: 19129463). Shows a pH-sensitive substrate specificity towards sulfated steroids, taurocholate and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment (PubMed: 19129463). Involved in the clearance of bile acids and organic anions from the liver (PubMed: 22232210). Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop (PubMed:22232210). Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition (PubMed:26383540). May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins) such as pitavastatin, a clinically important class of hypolipidemic drugs (PubMed: 15159445). May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drugs methotrexate and paclitaxel (PubMed: 23243220). May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver (PubMed: 16627748, PubMed:16624871).

Cellular Location

Basolateral cell membrane; Multi-pass membrane protein. Basal cell membrane; Multi-pass membrane protein. Note=Localized to the basolateral membrane of hepatocytes (PubMed:10779507). Localized to the basal membrane of Sertoli cells (PubMed:35307651)

Tissue Location

Highly expressed in liver, in particular at the basolateral membrane of hepatocytes near the central vein (PubMed:10779507, PubMed:15159445). Expressed in the placenta (PubMed:12409283). In testis, primarily localized to the basal membrane of Sertoli cells and weakly expressed in Leydig cells and within the tubules (PubMed:35307651).

SLCO1B3 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

SLCO1B3 Antibody (C-term) Blocking Peptide - Images

SLCO1B3 Antibody (C-term) Blocking Peptide - Background

SLCO1B3 belongs to the organic anion transporter (OATP)family. OATPs are involved in the membrane transport of bile acids, conjugated steroids, thyroid hormone, eicosanoids, peptides, andnumerous drugs in many tissues (Mikkaichi et al., 2004 [PubMed14993604]).

SLCO1B3 Antibody (C-term) Blocking Peptide - References

Hu, M., et al. Pharmacogenet. Genomics 20(10):634-637(2010)Weiner, M., et al. Antimicrob. Agents Chemother. 54(10):4192-4200(2010)Kang, T.W., et al. Hum. Mol. Genet. 19(18):3672-3678(2010)Takahashi, N., et al. J. Hum. Genet. (2010) In press: Justenhoven, C., et al. Breast Cancer Res. Treat. (2010) In press: